India, April 28 -- Actinium Pharmaceuticals, Inc. (ATNM), Monday announced preclinical results of ATNM-400, a novel, non-PSMA targeting, first in class targeted radiotherapy utilizing the Actinium-225 radioisotope for prostate cancer.
The data, presented at the American Association for Cancer Research Annual Meeting, showed that ATNM-400 outperforms Pluvicto, a prostate-specific membrane antigen.
The findings highlighted ATNM-400's potential as a transformative therapeutic option for prostate cancer patients with unmet clinical needs as expression of the target receptor for ATNM-400 persists following Pluvicto therapy and ATNM-400 demonstrates sustained tumor control after Pluvicto stops working.
googletag.cmd.push(function() { googletag...